抗恶性黑色素瘤的分子靶向治疗药物

Abstract
Figure/Table
References (25)
Related Citation (0)

Download: PDF (0 KB) HTML (45 KB)
Export: BibTeX | EndNote (RIS)

Abstract Melanoma is one of themalignant tumors that have highly received recent attention in recent years.In view of the deficiency in effective treatment formetastaticmalignantmelanoma,it is of great importance to find amore effective drug.This paper focused on the current situation of targeted therapy in the treatment ofmelanoma.Although the targeted therapy still had many problems to be resolved,its development and improvement in the melanoma treatment should not be ignored and a good application prospect could be expected.Through consultation,analysis and summarization of a large number of relevant domestic and overseas researches on targeted therapies formelanoma in recent years, the targeted therapeutic agents for anti-malignantmelanoma that are still under research and achieve some progress as well as their features and existing problems are summed up,which provides ideas and methods to study the targeted treatment formalignantmelanoma.

Key words： Malignantmelanoma Targeted therapy MAPK pathway c-kit pathway

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Ru-bing
	DING Bao-yue
	WU Zhao-yong
	SONG Jian-qin
	BAIHai-ting
	XU Ning-yin

Cite this article:

CHEN Ru-bing,DING Bao-yue,WU Zhao-yong, et al. M olecular targeted therapeutic agents for anti-malignantmelanoma[J]. 中国当代医药, 2016, 23(32): 11-13转86.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I32/11

[1]	CSCO黑色素瘤专家委员会.中国黑色素瘤诊治指南[M].2013版.北京：人民卫生出版社，2013：17-18.
[2]	Ferlay J，Steliarova-Foucher E，Lortet-Tieulent J，et al.Cancer incidence andmortality patterns in Europe：estimates for 40 countries in 2012[J].Eur JCancer，2013，49（6）：1374-1403.
[3]	Zuidervaart W，Van Nieuwpoort F，Stark M，et al.Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS[J].Br JCancer，2005，92（11）：2032-2038.
[4]	Bollag G，Hirth P，Tsai J，et al.Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma[J].Nature，2010，467（7315）：596-599.
[5]	Chapman PB，Hauschild A，Robert C，et al.Improved survivalwith vemurafenib inmelanomawith BRAF V600Emutation[J].N Engl JMed，2011，364（26）：2507-2516.
[6]	Hauschild A，Grob JJ，Demidov LV，et al.Dabrafenib in BRAF-mutated metastatic melanoma：a multicentre，openlabel，phase 3 randomised controlled trial[J].Lancet，2012，380（9839）：358-365.
[7]	Dummer R，Robert C，Gutzmer R，et al.Selumetinib plus dacarbazine versus placebo plus dacarbizine as first-line treatment for BRAF-mutantmetastaticmelanoma：a phase 2 doubleblind randomized study[J].Lancet Oncol，2013，14（8）：733-740.
[8]	Flaherty KT，Robert C，Hersey P，et al.Improved survival with MEK inhibition in BRAF-mutated melanoma[J].N Engl JMed，2012，367（2）：107-114.
[9]	Sosman JA，Kim KB，Schuchter L，et al.Survival in BRAF V600-mutantadvancedmelanoma treatedwith vemurafenib[J]. N Engl JMed，2012，366（8）：707-714.
[10]	Falchook GS，Long GV，Kurzrock R，et al.Dabrafenib in patients with melanoma，untreated brain metastases，and other solid tumours：a phase 1 dose-escalation trial[J]. Lancet，2012，379（9829）：1893-1901.
[11]	Porcelli L，Guida G，Tommasi S，et al.Metastatic melanoma cells with BRAF G469A mutation：nab-paclitaxel better than vemurafenib[J].Cancer Chemother Pharmacol，2015，76（2）：433-438.
[12]	Anforth R，Fernandez-Penas P，Long GV.Cutaneous toxicities of RAF inhibitors[J].Lancet Oncol，2013，14（1）：11-18.
[13]	Menzies AM，Yeh I，Botton T，et al.Clinical activity of the MEK inhibitor trametinib in metastatic melanomacontaining BRAF kinase fusion[J].Pigment Cell Melanoma Res，2015，28（5）：607-610.
[23]	Settleman J.A therapeutic opportunity in melanoma：ErbB4 makes a mark on skin[J].Cancer Cell，2009，16（4）：278-279.
[14]	Ascierto PA，Schadendorf D，Berking C，et al.MEK162 for patients with advanced melanomaharbouring NRAS or Val600 BRAF mutations：a non-randomised，open-labelphase 2 study[J].Lancet Oncol，2013，14（3）：249-256.
[15]	Ascierto PA，Minor D，Ribas A，etal.PhaseⅡtrial（BREAK-2）of the BRAF inhibitor dabrafenib（GSK2118436）in patientswith metastatic melanoma[J].JClin Oncol，2013，31（26）：3205-3211.[16]Larkin J，Ascierto PA，Dréno B，et al.Combined vemurafenib and cobimetinib in BRAF-mutated melanoma[J].N Engl JMed，2014，371（20）：1867-1876.
[17]	Robert C，Karaszewska B，Schachter J，et al.Improved overall survival in melanoma with combined dabrafenib and trametinib[J].N Engl JMed，2015，372（1）：30-39.
[18]	Ribas A，Gonzalez R，Pavlick A，et al.Combination of vemurafenib and cobimetinib in patients with advanced BRAF（V600）-mutated melanoma：a phase 1b study[J]. Lancet Oncol，2014，15（9）：954-965.
[19]	Sullivan RJ，Weber JS，Patel SP，et al.A phaseⅠb/Ⅱstudy of BRAF inhibitor（BRAFi）encorafenib（ENCO）plus MEK inhibitor（MEKi）binimetinib（BINI）in cutaneous melanoma patients naive to BRAFi treatment[J].ASCO Meet Abstr，2015，33（15）：9007.
[20]	Woodman SE，Trent JC，Stemke-Hale K，et al.Activity of dasatinib against L576PKITmutantmelanoma：molecular，cellular，and clinical correlates[J].Mol Cancer Ther，2009，8（8）：2079-2085.
[21]	Patel SP，Kim KB，Papadopoulos NE.A phaseⅡstudy of gefitinib in patientswithmetastaticmelanoma[J].Melanoma Res，2011，21（4）：357-363.
[22]	Schicher N，Paulitschke V，Swoboda A，et al.Erlotinib and bevacizumab have synergistic activity againstmelanoma[J]. Clin Cancer Res，2009，15（10）：3495-3502.
[24]	Djerf Severinsson EA，Trinks C，Grren H.The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis ofmalignantmelanoma in vitro and displays anti-tumor activity in vivo[J].Biochem Biophys Res Commun，2011，414（3）：563-568.
[25]	Soni S，Lee DS，DiVito J Jr，et al.Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide[J].JPediatr Hematol Oncol，2002，24（6）：488-491.